NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free CLPT Stock Alerts $5.94 +0.09 (+1.54%) (As of 12:06 PM ET) Add Compare Share Share Today's Range$5.89▼$6.0250-Day Range$5.26▼$7.2152-Week Range$4.05▼$9.29Volume31,924 shsAverage Volume141,987 shsMarket Capitalization$162.87 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ClearPoint Neuro alerts: Email Address ClearPoint Neuro MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.0% Upside$12.00 Price TargetShort InterestBearish4.96% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector2016th out of 2,771 stocksSurgical & Medical Instruments Industry226th out of 300 stocks 3.5 Analyst's Opinion Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.96% of the outstanding shares of ClearPoint Neuro have been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in ClearPoint Neuro has recently increased by 10.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLPT. Previous Next 3.3 News and Social Media Coverage News SentimentClearPoint Neuro has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ClearPoint Neuro this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.11% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by InstitutionsOnly 30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.63) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 6.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ClearPoint Neuro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About ClearPoint Neuro Stock (NASDAQ:CLPT)ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Read More CLPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLPT Stock News HeadlinesMay 11 at 2:29 AM | americanbankingnews.comClearPoint Neuro, Inc. to Post Q2 2024 Earnings of ($0.17) Per Share, B. Riley Forecasts (NASDAQ:CLPT)May 8, 2024 | msn.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comClearPoint Neuro Inc (CLPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth ...May 7, 2024 | finance.yahoo.comClearPoint Neuro Inc. Reports Strong Q1 2024 Performance, Surpassing Revenue ExpectationsMay 7, 2024 | msn.comCLPT Stock Earnings: ClearPoint Neuro Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comClearPoint Neuro Reports First Quarter 2024 ResultsMay 5, 2024 | americanbankingnews.comClearPoint Neuro (CLPT) to Release Earnings on TuesdayMay 2, 2024 | finance.yahoo.comClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in BaltimoreMay 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)May 1, 2024 | investorplace.com7 Penny Stocks That Could Make You a Fortune (If You Dare)April 29, 2024 | finance.yahoo.comClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor AccessoryApril 24, 2024 | finance.yahoo.comClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic SystemApril 23, 2024 | finance.yahoo.comClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024April 22, 2024 | markets.businessinsider.comClearPoint Neuro Poised for Growth: Strong Buy Rating Justified Amidst Market DipApril 19, 2024 | finance.yahoo.comIs There Now An Opportunity In ClearPoint Neuro, Inc. (NASDAQ:CLPT)?April 16, 2024 | globenewswire.comClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN MutationsApril 11, 2024 | investorplace.comThe 3 Most Promising MedTech Stocks to Invest In NowMarch 19, 2024 | globenewswire.comClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC DeficiencyMarch 16, 2024 | msn.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Annual Results: Here's What Analysts Are Forecasting For This YearMarch 14, 2024 | finance.yahoo.comClearPoint Neuro Full Year 2023 Earnings: Beats ExpectationsMarch 12, 2024 | finance.yahoo.comClearPoint Neuro Inc Reports Robust Revenue Growth in Q4 and Full-Year 2023March 12, 2024 | globenewswire.comClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 ResultsMarch 11, 2024 | markets.businessinsider.comClearPoint Neuro is about to announce its earnings — here's what Wall Street expectsMarch 11, 2024 | benzinga.comEarnings Outlook For ClearPoint NeuroSee More Headlines Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CLPT CUSIPN/A CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+105.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,090,000.00 Net Margins-78.84% Pretax Margin-78.84% Return on Equity-76.92% Return on Assets-43.94% Debt Debt-to-Equity RatioN/A Current Ratio3.14 Quick Ratio2.61 Sales & Book Value Annual Sales$23.95 million Price / Sales6.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book6.80Miscellaneous Outstanding Shares27,420,000Free Float25,745,000Market Cap$160.41 million OptionableOptionable Beta0.97 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Joseph Michael Burnett (Age 47)President, CEO & Director Comp: $803.12kMr. Danilo D'Alessandro (Age 38)Chief Financial Officer Comp: $459.26kMr. Jeremy Stigall (Age 40)Chief Business Officer Comp: $392.66kMr. Mazin Sabra (Age 43)Chief Operating Officer Ms. Ellisa CholapraneeGeneral Counsel & SecretaryMs. Jacqueline KellerVice President of MarketingMore ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHAlpha Tau MedicalNASDAQ:DRTSQuipt Home MedicalNASDAQ:QIPTAccurayNASDAQ:ARAYCVRxNASDAQ:CVRXView All CompetitorsInstitutional OwnershipCM Management LLCBought 175,000 shares on 5/14/2024Ownership: 1.368%Russell Investments Group Ltd.Bought 46,096 shares on 5/8/2024Ownership: 0.171%Essex Investment Management Co. LLCBought 329,879 shares on 5/3/2024Ownership: 1.219%Taylor Frigon Capital Management LLCBought 71,491 shares on 4/19/2024Ownership: 1.567%View All Institutional Transactions CLPT Stock Analysis - Frequently Asked Questions Should I buy or sell ClearPoint Neuro stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ClearPoint Neuro in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLPT shares. View CLPT analyst ratings or view top-rated stocks. What is ClearPoint Neuro's stock price target for 2024? 3 brokerages have issued 12-month target prices for ClearPoint Neuro's shares. Their CLPT share price targets range from $9.00 to $15.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 102.0% from the stock's current price. View analysts price targets for CLPT or view top-rated stocks among Wall Street analysts. How have CLPT shares performed in 2024? ClearPoint Neuro's stock was trading at $6.79 at the beginning of 2024. Since then, CLPT stock has decreased by 12.5% and is now trading at $5.94. View the best growth stocks for 2024 here. When is ClearPoint Neuro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CLPT earnings forecast. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) released its earnings results on Tuesday, March, 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. The business earned $6.81 million during the quarter, compared to analysts' expectations of $6.40 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 76.92% and a negative net margin of 78.84%. What guidance has ClearPoint Neuro issued on next quarter's earnings? ClearPoint Neuro updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $28.0 million-$32.0 million, compared to the consensus revenue estimate of $30.3 million. Who are ClearPoint Neuro's major shareholders? ClearPoint Neuro's stock is owned by many different institutional and retail investors. Top institutional investors include Taylor Frigon Capital Management LLC (1.57%), CM Management LLC (1.37%), Essex Investment Management Co. LLC (1.22%), Russell Investments Group Ltd. (0.17%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLPT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
